Clinical trials in JON-HBP

22/9/2025 updated

JON2101-H Randomized phase III trial of Lenvatinib versus Ramucirumab as a second-line treatment after immune check-point inhibitor for advanced hepatocellular carcinoma with alfa-fetoprotein >400 ng/mL (SELECT-400)
JON2102-H Randomized phase III trial of Sorafenib versus Lenvatinib as a second-line treatment after immune check point inhibitor for advanced hepatocellular carcinoma (JON2102-H (SUCCEED)
JON2108-O Master protocol trial for rare fractions of hepato-pancreato-biliary cancer and neuroendocrine tumor.
JON2201-P The effect of adjuvant chemotherapy on the prognosis in the patients with familial pancreatic cancer
JON2301-H Lenvatinib plus cisplatin hepatic arterial infusion chemotherapy for borderline resectable hepatocellular carcinoma: A Multicenter Phase II Study(LEOPARD-Neo)
JON2105-P Phase II study of FOLFOX for unresectable pancreatic cancer patients with germline BRCA pathogenic variant
JON2202-B A multicenter single arm phase I study of concurrent radiation and gemcitabine plus cisplatin with durvalumab (MEDI4736) for advanced biliary tract cancer (MARVEL trial)
JON2302-P A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy
JON2303-B Real-world data analysis of pemigatinib therapy for unresectable or recurrent biliary tract cancer patients with FGFR2 fusion or FGFR2 rearrangement
JON2203-N A multicenter observational study to evaluate the efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in patients with unresectable neuroendocrine tumors (NEN).
JON2305-N Updated Analysis of Treatment Outcomes with Temozolomide Plus Capecitabine in Patients with Pancreatic Neuroendocrine Tumors in Japan (2023-2024)
JON2306-B A prospective, multicenter, phase II trial of platinum re-introduction withgemcitabine after gemcitabine and cisplatin with durvalumab (MEDI4736)in patients with biliary tract cancer (PRIDE study)
JON2307-B A Retrospective Study of Biliary Complications and treatment duration in Patients with Biliary Tract Cancer Receiving Systemic Therapy in Japan (ARCBile study)
JON2304-H Phase II study of durvalumab monotherapy for patients with unresectable hepatocellular carcinoma and Child-Pugh B
JON2401-B

A Randomized Controlled Trial of　Hepatectomy versus Hepatectomy plus Regional Lymphadenectomy in Patients with Clinical N0 Intrahepatic Cholangiocarcinoma